BIOCYTOGEN-B RenMab technology platform has been granted a new patent in Japan, continuing to deepen the global patent layout of the RenMice full human antibody/TCR platform

According to the Zhitong Finance APP, BIOCYTOGEN-B (02315) announced that its independently developed fully human antibody mouse RenMab® platform has received an invention patent certificate issued by the Japan Patent Office (JPO). This marks another key advancement in the global intellectual property protection of BIOCYTOGEN's RenMice® fully human antibody platform family, signifying the steady progress and deepening of its systematic global patent layout strategy, fully demonstrating the innovation and international recognition of its core technology. RenMab® mice are one of the core members of BIOCYTOGEN's independently developed RenMice® fully human antibody discovery platform family. BIOCYTOGEN utilizes its unique super-large fragment chromosome engineering technology (SUPCE®) to replace the variable region genes of the mouse's heavy and light chain antibodies in situ with the corresponding human genes. As a result, RenMab mice possess complete human antibody heavy chain VDJ genes and light chain VJ genes, and like wild mice, RenMab mice can generate strong immune responses against different antigens, producing fully human antibody molecules that maximally retain natural diversity, significantly improving the success rate of discovering high-potential antibody drug molecules. The fully human antibody molecules produced by RenMab mice do not require complex humanization modifications, effectively reducing the immunogenicity risk during the antibody drug development process, greatly enhancing research and development efficiency and success rates. The RenMice® series mouse platform (including RenMab®, RenLite®, RenNano®, RenTCR-mimic®, and RenTCR™) has demonstrated outstanding advantages in discovering low immunogenicity, high diversity, high affinity, and excellent physicochemical properties of fully human antibodies/TCRs, and has received widespread recognition from top global pharmaceutical and biotechnology companies. BIOCYTOGEN has established licensing collaborations for the RenMice platform with approximately 20 leading domestic and international companies, including Merck Germany, Janssen/Johnson & Johnson, and BeiGene. Based on the "thousand mice and ten thousand antibodies" project of the RenMice platform, which generates millions of fully human antibody molecules targeting thousands of potential drug targets, and high-potential preclinical candidate antibody molecules, by the end of 2024, BIOCYTOGEN has achieved nearly 200 licensing/transfer collaborations for antibody molecules, fully proving the international competitiveness and commercial value of the RenMice platform. With continuous independent research and development and underlying technological innovation capabilities, BIOCYTOGEN is actively conducting patent layout and key technology protection for the RenMice® platform globally. As of now, the RenMice platform has obtained patent authorization in nearly 10 countries, including the United States, China, and Japan, and has nearly 40 patent applications in 15 countries and regions advancing to the examination stage, with the expectation of obtaining more patent authorizations in the future. The steady advancement of BIOCYTOGEN's global patent layout strategy will continue to provide solid intellectual property protection for global partners